Anemia Management in CKD: Updates and Best Practices

This engaging session discusses the growing prevalence of chronic kidney disease (CKD) and the multifaceted challenges in its management, with a focus on anemia—a common and significant complication. Through expert insights, the dialogue explores the evolving role of iron supplementation and erythropoiesis-stimulating agents (ESAs), alongside the emerging use of hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) as novel therapeutic options. In collaboration with the American Society of Nephrology, this session aims to equip nephrologists with practical, evidence-based strategies to optimize anemia care and improve outcomes in CKD patients.